These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 22203906)
1. Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease). Spuch C; Navarro C J Drug Deliv; 2011; 2011():469679. PubMed ID: 22203906 [TBL] [Abstract][Full Text] [Related]
2. Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases. Seo MW; Park TE Biomed Eng Lett; 2021 Aug; 11(3):211-216. PubMed ID: 34350048 [TBL] [Abstract][Full Text] [Related]
3. Advances in the treatment of neurodegenerative disorders employing nanoparticles. Spuch C; Saida O; Navarro C Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):2-18. PubMed ID: 22272933 [TBL] [Abstract][Full Text] [Related]
4. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Teixeira MI; Lopes CM; Amaral MH; Costa PC Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574 [TBL] [Abstract][Full Text] [Related]
5. Liposome based drug delivery as a potential treatment option for Alzheimer's disease. Hernandez C; Shukla S Neural Regen Res; 2022 Jun; 17(6):1190-1198. PubMed ID: 34782553 [TBL] [Abstract][Full Text] [Related]
6. Alzheimer's Disease and Parkinson's Disease: A Review of Current Treatment Adopting a Nanotechnology Approach. Trompetero A; Gordillo A; Del Pilar MC; Cristina VM; Bustos Cruz RH Curr Pharm Des; 2018; 24(1):22-45. PubMed ID: 28847307 [TBL] [Abstract][Full Text] [Related]
7. Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer's and Parkinson's diseases. Attia MS; Yahya A; Monaem NA; Sabry SA Saudi Pharm J; 2023 Mar; 31(3):417-432. PubMed ID: 37026045 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems. Cunha S; Amaral MH; Lobo JM; Silva AC Curr Med Chem; 2016; 23(31):3618-3631. PubMed ID: 27554805 [TBL] [Abstract][Full Text] [Related]
10. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances. Niu X; Chen J; Gao J Asian J Pharm Sci; 2019 Sep; 14(5):480-496. PubMed ID: 32104476 [TBL] [Abstract][Full Text] [Related]
11. Strategies for brain-targeting liposomal delivery of small hydrophobic molecules in the treatment of neurodegenerative diseases. Wang ZY; Sreenivasmurthy SG; Song JX; Liu JY; Li M Drug Discov Today; 2019 Feb; 24(2):595-605. PubMed ID: 30414950 [TBL] [Abstract][Full Text] [Related]
17. Nanotheranostic agents for neurodegenerative diseases. Padmanabhan P; Palanivel M; Kumar A; Máthé D; Radda GK; Lim KL; Gulyás B Emerg Top Life Sci; 2020 Dec; 4(6):645-675. PubMed ID: 33320185 [TBL] [Abstract][Full Text] [Related]
18. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Cacciatore I; Ciulla M; Fornasari E; Marinelli L; Di Stefano A Expert Opin Drug Deliv; 2016 Aug; 13(8):1121-31. PubMed ID: 27073977 [TBL] [Abstract][Full Text] [Related]
19. Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers. Tonda-Turo C; Origlia N; Mattu C; Accorroni A; Chiono V Curr Med Chem; 2018; 25(41):5755-5771. PubMed ID: 29473493 [TBL] [Abstract][Full Text] [Related]
20. Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases. Pandian SRK; Vijayakumar KK; Murugesan S; Kunjiappan S Heliyon; 2022 Jun; 8(6):e09575. PubMed ID: 35706935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]